Bafna Pharmaceuticals Ltd
Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD
Stock has not been able to generate better return on equity than bank FD
Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company
Stock doesn't offer attractive dividend returns
Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock
Good time to consider, as stock is not in overbought zone
No Red FlagsASM and GSM lists are measures to safeguard investors against volatility and unjustified stock prices. Pledging holdings means taking loans against held promoter shares. Stocks in ASM/GSM list or with high pledged promoter holding should be handled with caution. Unsolicited tips are sometimes circulated to manipulate the market. Beware of these stocks
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Bafna Pharmaceuticals Ltd
BAFNAPH
Price Chart
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Insufficient Data
Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD
Stock has not been able to generate better return on equity than bank FD
Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company
Stock doesn't offer attractive dividend returns
Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock
Good time to consider, as stock is not in overbought zone
No Red FlagsASM and GSM lists are measures to safeguard investors against volatility and unjustified stock prices. Pledging holdings means taking loans against held promoter shares. Stocks in ASM/GSM list or with high pledged promoter holding should be handled with caution. Unsolicited tips are sometimes circulated to manipulate the market. Beware of these stocks
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Key Metrics
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Gland Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.34%
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Bafna Pharma in talks with multinational pharma firms for brand acquisition
2 weeks ago•Free Press Journal
In talks with MNCs pharma cos for acquisition of brands: Bafna pharma
3 weeks ago•Business Standard
In talks with multinational pharma cos for acquisition of brands: Bafna pharmaceuticals
3 weeks ago•Economic Times
Recent EventsAll events
Rights Issue
3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including the provisions of the Securities and Exchange Board of India (lssue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and the Rules made there under and as amended.The proposed Rights Issue will be a step towards meeting with the Minimum Public Shareholding requirements and is one of the prescribed methods in accordance with SEBI Circular No. CIR/CFD/CMD/14/2015 dated November 30, 2015, as amended. Accordingly, the Promoter may not participate in the proposed Rights Issue. | Download
3. Raising of funds by way of offer and issue of equity shares to the existing shareholders of the Company on a rights basis (Rights Issue) for an aggregate amount upto INR 50 Crore. The Board has constituted a Rights Issue Committee of Directors for the above purpose and has authorised the Committee to determine the terms of the Rights Issue including the quantum of issue, rights entitlement ratio, issue price, issue size, book closure or record date, entitlement timing of the issue, appointment of intermediaries, etc., in consultation with the Lead Manager to the Right Issue and to decide all other matters relating to the Right Issue. Such details shall be informed and/or announced in due course as and when decided or required, as per applicable statutory provisions and depending upon the market conditions. The above proposal to issue of shares shall be subject to necessary approvals, confirmations and consents as may be necessary and in compliance with applicable law including the provisions of the Securities and Exchange Board of India (lssue of Capital and Disclosure Requirements) Regulations, 2018 and the Companies Act, 2013 and the Rules made there under and as amended.The proposed Rights Issue will be a step towards meeting with the Minimum Public Shareholding requirements and is one of the prescribed methods in accordance with SEBI Circular No. CIR/CFD/CMD/14/2015 dated November 30, 2015, as amended. Accordingly, the Promoter may not participate in the proposed Rights Issue. | Download
Cash Dividend
Final • Div/Share: ₹ 0.6
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Insufficient Data